Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 11/20 | 0.49 |
| ▸ | VDR | P11473 | 10/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | RHEB | Q15382 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1251505 | 0.89 | NR1H4 (0.43) | NR1H4VDRPTGER4PIN1 | |
| SCHEMBL3171773 | 0.87 | PTGER4 (0.48) | NR1H4PTGER4PDE2APIN1ACSS2 | |
| SCHEMBL3167934 | 0.87 | PTGER4 (0.49) | NR1H4VDRPTGER4PIN1ACSS2 | |
| SCHEMBL3171231 | 0.83 | PTGER4 (0.48) | NR1H4VDRPTGER4PIN1ACSS2 | |
| SCHEMBL3175866 | 0.83 | VDR (0.55) | NR1H4VDRPDE2ASLC22A12 | |
| SCHEMBL3176844 | 0.82 | PIN1 (0.52) | NR1H4VDRPTGER4PIN1RHEB | |
| SCHEMBL1248717 | 0.81 | DGAT1 (0.48) | PDE2AACSS2 | |
| SCHEMBL1249431 | 0.75 | VDR (0.55) | NR1H4VDRPTGER4SLC22A12 | |
| SCHEMBL6170515 | 0.75 | SLC22A12 (0.58) | NR1H4VDRACSS2SLC22A12 | |
| SCHEMBL15644808 | 0.74 | SMN1; SMN2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | claimed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | claimed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20100016387-A1 | METHOD OF TREATMENT | BOSE AVIRUP | 2010-01-21 | — | — | US | disclosed |
| EP-2101783-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | Novartis Ag (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | disclosed |
| WO-2008073865-A2 | METHOD OF PREVENTING OR TREATING MYOCARDIAL ISCHEMIA | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016387-A1 | METHOD OF TREATMENT | DGAT1, DGAT2, DGKA | NR1H4 611/4885VDR 2902/4885PTGER4 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.